Beyond Air, Inc. (XAIR) Announces Positive Preclinical Data Supporting High Concentration Nitric Oxide as a Potential Treatment for Solid Tumors

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. HOOD
8. DFTX
9. MU
10. IBM

Go back to Beyond Air, Inc. (XAIR) Announces Positive Preclinical Data Supporting High Concentration Nitric Oxide as a Potential Treatment for Solid Tumors

Beyond Air Announces Positive Preclinical Data Supporting High Concentration Nitric Oxide as a Potential Treatment for Solid Tumors

June 22, 2020 9:00 AM EDT

Data demonstrate the ablation of solid tumors with nitric oxide

All tumor-bearing mice treated with nitric oxide rejected a second tumor challenge, suggesting induction of an anti-tumor immune response

GARDEN CITY, N.Y., June 22, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid... More